Is Dr. Lal PathLabs (LALPATHLAB) overvalued or fairly valued?

MarketChacha shows Dr. Lal PathLabs's valuation in context — a forward P/E of about 41.1, a price-to-book of about 11.3 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Dr. Lal PathLabs's revenue?

Dr. Lal PathLabs reported revenue of ₹2,648 Cr for FY2026, with net profit of ₹508 Cr, per official filings.

What is the share price of Dr. Lal PathLabs (LALPATHLAB)?

Dr. Lal PathLabs last traded at ₹1,694.00 (+0.4% on the day), as of 7/21/2026 — a delayed quote shown for education, not investment advice.

Dr. Lal PathLabs

LALPATHLAB · NSE · Diagnostics · India

₹1,694.00+0.4%

Delayed · as reported by Yahoo Finance · as of Jul 21, 2026, 5:40 AM

Snapshot

TickerLALPATHLAB

ExchangeNSE

SectorDiagnostics

IndustryDiagnostics & Research

CountryIndia

CEOMr. Shankha Banerjee

Employees5,206

HeadquartersGurugram, India

Market cap₹28,274 Cr

P/B11.3

Volume16.54K

Websitewww.lalpathlabs.com

Filings tracked0

About Dr. Lal PathLabs

Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomist training programs. The company was founded in 1949 and is based in Gurugram, India.

Profile as reported by Yahoo Finance.

Who owns it

Promoters54.9%
Institutions31.5%
Public & other13.6%

105 institutional holders

As reported by Yahoo Finance. Promoter pledge is not included here — that comes from exchange shareholding filings.

What's expected next

Next quarter

Rev ₹826 Cr · EPS 10.15

Est. earnings growth +12.8%

Next fiscal year

Rev ₹3,552 Cr · EPS 41.24

Est. earnings growth +16.7%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

₹1,272.6052-wk range₹1,803.00

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: BSE (official results filing)

Quarterly · last 2

Market cap

₹28,274 Cr

Day change

+0.4%

Fwd P/E

41.1

P/B

11.3

Div yield

0.83%

Beta

0.19

Revenue (FY2026)

₹2,648 Cr

Net margin

19.2%

EPS (FY2026)

30.45

Net profit (FY2026)

₹508 Cr

Market figures: Delayed · as reported by Yahoo Finance. Financials as reported in company filings.

Ask MarketChacha about LALPATHLAB

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin
FY2026	₹2,648 Cr	₹508 Cr	30.45	19.2%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q1	₹675 Cr	₹141 Cr	8.45	20.9%
2025Q4	₹632 Cr	₹92 Cr	5.52	14.6%

Figures as reported, in ₹ (crore). Source: BSE (official results filing).

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.